Abstract
Background. After progression on endocrine therapy combined with palbociclib in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer, a practical question arises regarding subsequent treatment: whether it is appropriate to reuse the same cyclin-dependent kinase inhibitor with a change in the endocrine partner, whether it is more rational to switch to another agent in this class, or whether to proceed only with the next line of endocrine therapy.Purpose – to assess the clinical appropriateness of palbociclib rechallenge and the strategy of switching cyclin-dependent kinase inhibitors after progression on palbociclib in metastatic breast cancer.Materials and Methods. A narrative literature review was performed. Sources were searched in PubMed/MEDLINE, Scopus, and ClinicalTrials.gov over the last seven years (2020–2026); supplementary searches for guidelines, congress materials, and regulatory documents were performed using Google Scholar. The analysis included randomized clinical trials, meta-analyses, reviews, and current clinical guidelines addressing treatment after progression on palbociclib.Results. The analysis showed that continuing therapy with the same inhibitor, particularly palbociclib, while changing the underlying endocrine therapy does not lead to a statistically significant improvement in progression-free survival, indicating the development of stable cross-resistance and making this approach clinically unjustified. In contrast, switching to another cyclin-dependent kinase inhibitor, primarily abemaciclib or ribociclib, is associated with more stable disease control and a more favorable balance between expected benefit and risk. It was additionally established that treatment selection after progression is increasingly determined by the molecular tumor profile, because alterations in estrogen receptor signaling, the phosphatidylinositol 3-kinase cascade, and loss of function of suppressor regulators may affect sensitivity to subsequent endocrine and targeted therapy, requiring the use of newer selective estrogen receptor degraders or targeted inhibitors.Conclusions. After progression on palbociclib, preference should be given not to routine rechallenge with the same drug, but to an individualized strategy involving a change of cyclin-dependent kinase inhibitor and consideration of the molecular characteristics of the tumor.

This publication has 27 references indexed in Scilit: